373 related articles for article (PubMed ID: 14523280)
1. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
[TBL] [Abstract][Full Text] [Related]
2. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
[TBL] [Abstract][Full Text] [Related]
3. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M;
AIDS; 2007 May; 21(9):1185-97. PubMed ID: 17502729
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
7. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Writing Committee for the CASCADE Collaboration
Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
[TBL] [Abstract][Full Text] [Related]
8. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
9. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
Krentz HB; Kliewer G; Gill MJ
HIV Med; 2005 Mar; 6(2):99-106. PubMed ID: 15807715
[TBL] [Abstract][Full Text] [Related]
10. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
11. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A; Phillips AN; d'Arminio Monforte A; Castelli F; Antinori A; de Luca A; Pezzotti P; Alberici F; Cargnel A; Grima P; Piscopo R; Prestileo T; Scalise G; Vigevani M; Moroni M;
AIDS; 2001 May; 15(8):983-90. PubMed ID: 11399980
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
[TBL] [Abstract][Full Text] [Related]
13. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
14. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
[TBL] [Abstract][Full Text] [Related]
15. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
[TBL] [Abstract][Full Text] [Related]
17. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.
Abaasa AM; Todd J; Ekoru K; Kalyango JN; Levin J; Odeke E; Karamagi CA
BMC Health Serv Res; 2008 Nov; 8():241. PubMed ID: 19021908
[TBL] [Abstract][Full Text] [Related]
18. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
19. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA;
Lancet; 2002 Jul; 360(9327):119-29. PubMed ID: 12126821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
